Published in Hematol J on January 01, 2003
Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'-UTR of the HAMP gene. Blood (2004) 1.64
Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation (2012) 1.57
Fluvastatin increases the expression of adhesion molecules, monocyte chemoattractant protein-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies. Thromb Haemost (2005) 1.47
Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet (2002) 1.44
A model for the harmonisation of test results of different quantitative D-dimer methods. Thromb Haemost (2006) 1.42
[Carotid stents: role of evidence-based medicine!]. Rev Med Suisse (2010) 1.40
Influence of antidepressants on hemostasis. Dialogues Clin Neurosci (2007) 1.23
Minimizing perioperative blood loss and transfusions in children. Can J Anaesth (2006) 1.00
Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost (2002) 0.97
Clinical usefulness of D-dimer depending on clinical probability and cutoff value in outpatients with suspected pulmonary embolism. Arch Intern Med (2004) 0.96
Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides. Mol Immunol (2008) 0.95
NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost (2002) 0.94
The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood (2006) 0.93
Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model. Crit Care Med (2002) 0.93
Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth (2006) 0.92
Combined factor V - factor VIII deficiency (F5F8D): compound heterozygosity for two novel truncating mutations in LMAN1 in a consanguineous patient. Thromb Haemost (2006) 0.91
Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood (2011) 0.90
Deletion of 3 residues from the C-terminus of MCFD2 affects binding to ERGIC-53 and causes combined factor V and factor VIII deficiency. Blood (2007) 0.88
Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun (2004) 0.88
Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. BJOG (2004) 0.87
Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations. Hum Mutat (2007) 0.87
Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream? Semin Thromb Hemost (2008) 0.85
Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J (2010) 0.85
Purpura fulminans in a child as a complication of chickenpox infection. Dermatology (2004) 0.84
Efficacy of individual nucleic acid amplification testing in reducing the risk of transfusion-transmitted hepatitis B virus infection in Switzerland, a low-endemic region. Transfusion (2010) 0.84
Receptors involved in cell activation by antiphospholipid antibodies. Thromb Res (2013) 0.82
Agreement of a new whole-blood PT/INR test using capillary samples with plasma INR determinations. Thromb Res (2005) 0.82
Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation. BMC Gastroenterol (2010) 0.82
Inflammatory and prothrombotic states in obese children of European descent. Obesity (Silver Spring) (2012) 0.82
Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion (2005) 0.81
Pulmonary embolism and fatal stroke in a patient with severe factor XI deficiency after bariatric surgery. Blood Coagul Fibrinolysis (2013) 0.81
Fibrin D-dimer testing for venous and arterial thrombotic disease. Semin Vasc Med (2005) 0.80
A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism. Thromb Haemost (2008) 0.80
Acquired factor XIII deficiency: a therapeutic challenge. Thromb Haemost (2013) 0.80
Anticoagulants in portal vein thrombosis: don't be so shy! Blood (2009) 0.80
Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients. Thromb Haemost (2011) 0.79
Anti-beta(2)-glycoprotein I ELISA assay: the influence of different antigen preparations. Thromb Haemost (2009) 0.79
Evaluation of the CoaguChek XS Plus system in a Swiss community setting. Thromb Haemost (2009) 0.79
Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci (Lond) (2008) 0.79
Fibrinogen geneva II: a new congenitally abnormal fibrinogen alpha chain (Gly17Asp) with a review of similar mutations resulting in abnormal knob A. Blood Coagul Fibrinolysis (2014) 0.79
Implementation of an INR self-testing and self-management programme in common ambulatory private practice: our experience with 90 patients. Swiss Med Wkly (2011) 0.78
Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res (2004) 0.78
Superficial thrombophlebitis of the chest wall associated with anticardiolipin antibodies: antiphospholipid syndrome or Mondor's disease? Lupus (2004) 0.78
Variability between laboratories performing coagulation tests with identical platforms: a nationwide evaluation study. Thromb J (2013) 0.77
Evaluation of advanced D-dimer assay for the exclusion of venous thromboembolism. Thromb Res (2002) 0.77
Acquired and transient RBC CD55 deficiency (Inab phenotype) and anti-IFC. Transfusion (2002) 0.77
Hypodysfibrinogenaemia due to production of mutant fibrinogen alpha-chains lacking fibrinopeptide A and polymerisation knob 'A'. Thromb Haemost (2010) 0.77
Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays. Thromb Haemost (2005) 0.76
Immunization of LDL receptor-deficient mice with beta2-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques. Thromb Haemost (2007) 0.76
An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay results. Ann N Y Acad Sci (2007) 0.76
Heparin-induced thrombocytopenia associated with interleukin-8-dependent platelet activation in a patient with antiphospholipid syndrome. Eur J Haematol (2007) 0.76
Anti-beta2-glycoprotein I antibodies--when and how should they be measured? Thromb Res (2004) 0.76
Antiphospholipid antibodies and risk for recurrent vascular events. JAMA (2004) 0.75
Aspirin response variability assessed with the PFA-100 device. Thromb Haemost (2008) 0.75
Aspirin or clopidogrel for secondary prevention of cardiovascular events: is there a winner? Am J Med (2004) 0.75
[Two new very promising antithrombotic agents: pentasaccharide and ximelagatran]. Rev Med Suisse Romande (2002) 0.75
A novel frameshift mutation in FGA (c.1846 del A) leading to congenital afibrinogenemia in a consanguineous Syrian family. Blood Coagul Fibrinolysis (2011) 0.75
[Patient education and illiteracy in Switzerland]. Rev Med Suisse (2008) 0.75
Point of care management of heparin administration after heart surgery: A randomized, controlled trial. Intensive Care Med (2006) 0.75
[Peripheric arteriopathy: focus in 2007]. Rev Med Suisse (2007) 0.75
Felty's syndrome and hypofibrinogenemia: an unusual target for anti-cyclic citrullinated peptide antibodies? Mod Rheumatol (2015) 0.75
Endothelial cell activation by immunoglobulins from patients with immune thrombocytopenic purpura or with antiphospholipid syndrome. Haematologica (2008) 0.75
Severe bleeding and miscarriages in a hypofibrinogenemic woman heterozygous for the gamma Ala82Gly mutation. Blood Coagul Fibrinolysis (2009) 0.75
Quality control of fibrinogen secretion in the molecular pathogenesis of congenital afibrinogenemia. Hum Mol Genet (2005) 0.75
Homozygosity for a Thr575Met missense mutation in the catalytic domain associated with factor XI deficiency. Haematologica (2005) 0.75
Discrepancy between capillary and venous International Normalised Ratio (INR) in a patient on vitamin-K antagonist: potentially serious clinical consequences. Thromb Haemost (2006) 0.75
[Oral anticoagulants and directly observed therapy: the necessity of continuous education]. Rev Med Suisse (2014) 0.75
[Transfusion safety, time for a new partnership between stake-holders]. Rev Med Suisse (2006) 0.75
Extensive thromboembolic event as initial presentation of monoclonal gammopathy of undetermined significance. Thromb Haemost (2006) 0.75
[Why read the articles in this issue of Angiology and Hemostasis]. Rev Med Suisse (2011) 0.75
Identification and functional characterization of a novel nonsense mutation in FGA accounting for congenital afibrinogenemia in six Egyptian patients. Blood Coagul Fibrinolysis (2010) 0.75
[What is the role for the non-specialist physician in the care of patients with hemophilia?]. Rev Med Suisse (2008) 0.75
Diagnosis and management of obstetrical antiphospholipid syndrome: where do we stand? Pol Arch Med Wewn (2013) 0.75
[Evaluating the biological efficacy of clopidogrel: genotype or phenotype?]. Rev Med Suisse (2010) 0.75
[Angiography: need for a multidisciplinary approach]. Rev Med Suisse (2009) 0.75
Mutation of the translation initiation codon in FGA causes congenital afibrinogenemia. Blood Coagul Fibrinolysis (2012) 0.75
A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis. Blood Coagul Fibrinolysis (2008) 0.75
Congenital afibrinogenemia: identification and expression of a missense mutation in FGB impairing fibrinogen secretion. Blood (2003) 0.75
[Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse (2007) 0.75
Fibrinogen Krakow: a novel hypo/dysfibrinogenemia mutation in fibrinogen gamma chain (Asn325Ile) affecting fibrin clot structure and function. Thromb Haemost (2009) 0.75
Identification of a novel F11 missense mutation (Ile463Ser) in a family with congenital factor XI deficiency. Blood Coagul Fibrinolysis (2012) 0.75
[Introduction of acenocoumarol using an algorithm for prescription]. Rev Med Suisse (2010) 0.75